Why Poseida Therapeutics Shares Are Trading Higher By 219

1 day ago · Shares of Poseida Therapeutics, Inc. PSTX rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. Poseida Therapeutics …

CouponFollow Extension

$1
OFF

Why Poseida Therapeutics Shares Are Trading Higher By 219

2 days from now

1 day ago · Shares of Poseida Therapeutics, Inc. PSTX rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. Poseida Therapeutics …

benzinga.com

$1
OFF

Why Poseida Therapeutics Shares Are Trading Higher By… - Inkl

2 days from now

1 day ago · Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. …

inkl.com

219%
OFF

Why Poseida Therapeutics Shares Are Trading Higher By 219%; …

2 days from now

1 day ago · Shares of Poseida Therapeutics, Inc. NASDAQ:PSTX rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion …

tradingview.com

$1
OFF

Roche To Acquire Cell Therapy Maker Poseida Therapeutics In $1.5 ...

2 days from now

1 day ago · ZURICH (Reuters) - Switzerland's Roche will acquire its U.S. collaboration partner Poseida Therapeutics in a cash deal worth up to $1.5 billion, banking on complex immune cell …

usnews.com

$1
OFF

Roche To Acquire Poseida For Up To $1.5 Bln - Nasdaq

2 days from now

1 day ago · Roche will start a tender offer to acquire Poseida's outstanding shares for $9.00 per share in cash at closing, plus a contingent value right or CVR offering milestone payments up …

nasdaq.com

56%
OFF

Are You Looking For A Top Momentum Pick? Why Poseida …

2 days from now

Jul 19, 2024 · Shares of Poseida Therapeutics, Inc. Have increased 57.56% over the past quarter, and have gained 67.36% in the last year. On the other hand, the S&P 500 has only …

yahoo.com

6%
OFF

Why Poseida Therapeutics Almost Doubled Today, Here Are 75 …

2 days from now

Aug 3, 2022 · Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings …

businessinsider.com

49%
OFF

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

2 days from now

5 days ago · Poseida Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 273rd out of 946 stocks in the medical sector. Scores are calculated …

marketbeat.com

70%
OFF

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% In One Week

2 days from now

Nov 12, 2024 · Over the past quarter, shares of Poseida Therapeutics, Inc. Have risen 25.34%, and are up 76.67% in the last year. On the other hand, the S&P 500 has only moved 12.69% …

nasdaq.com

FAQs about Why Poseida Therapeutics Shares Are Trading Higher By 219 Coupon?

How did poseida Therapeutics' stock perform in 2024?

Poseida Therapeutics' stock was trading at $3.36 on January 1st, 2024. Since then, PSTX stock has decreased by 18.2% and is now trading at $2.75. View the best growth stocks for 2024 here. How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) issued its quarterly earnings data on Monday, August, 5th. ...

How much did poseida Therapeutics raise in an IPO?

Poseida Therapeutics (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO. Who are Poseida Therapeutics' major shareholders? ...

Is poseida Therapeutics a good stock to buy?

Poseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Poseida Therapeutics has only been the subject of 1 research reports in the past 90 days. Read more about Poseida Therapeutics' stock forecast and price target. ...

Will Roche buy poseida Therapeutics?

REUTERS/Arnd Wiegmann/File Photo By Dave Graham and Ludwig Burger ZURICH (Reuters) - Switzerland's Roche will acquire its U.S. collaboration partner Poseida Therapeutics in a cash deal worth up to $1.5 billion, banking on complex immune cell therapies against several types of blood cancer to boost its development pipeline. ...

Who owns poseida Therapeutics?

Top institutional shareholders of Poseida Therapeutics include Blair William & Co. IL (1.14%), Renaissance Technologies LLC (0.88%), Dimensional Fund Advisors LP (0.62%) and Acadian Asset Management LLC (0.41%). Insiders that own company stock include Life Sciences Holdings L Malin, Eric Ostertag and Kerry D Ingalls. ...

Is poseida Therapeutics (PsTx) a great choice Momentum Stock?

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. ...